Work

Abstract CT187: Immunogenicity of the therapeutic HPV16-specific cancer vaccine abipapogene suvaplasmid (VB10.16) in combination with pembrolizumab given as 1L treatment for HPV16+ PD-L1+ r/m oropharyngeal cancer: Preliminary results from phase 1 of the VB-C-03 trial

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct187

Authors: Caroline Even, Saira Khalique, Marc B. Oliva, Marie Vinches, Marta G. Arnau, Kaja C. Berg, Ingvild S. Leikfoss, Aleksandra Urban, Marthe J. Jørgensen, Christian W. Wold, Judith Wong, Miriam Ragle Aure, Lena Finnesand, Roberto Oliveri, Agnete B. Fredriksen, Åse Bratland

Institutions: Institut Gustave Roussy, Mount Vernon Cancer Centre, Institut Català d'Oncologia, Duran i Reynals Hospital, Institut Regional du Cancer de Montpellier, Hospital Del Mar, Parc de Salut, Oslo University Hospital

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154701847

Cites:

Cited by:

Related to: